Upendra Topiwala, PhD

Professional summary
Respected published and patented chemist whose knowledge of competitive intellig
ence utilizing secondary research, managing project databases, and interpreting
complex data to address scientific hypotheses helps companies bring new pharmace
utical discoveries to market. Synthesizes vast amounts of research into market
ing presentations that are both easily understood and compelling. As a project
leader and combining both scientific background and experience in technology tr
ansfer and laboratory research, fostered strategic internal and external partner
ships to create smooth transitions.
Employment history
Office of Technology Commercialization, Rutgers University, Intern: 2010.
As an expert in the therapeutic areas of Central Nervous System disorders and pa
in, assisted with the promotion of new pharmaceutical and medical device technol
ogies developed at Rutgers University by presenting strategic information to pot
ential clients. Gathered scientific content from patents, journals, several noti
ces of inventions, and patent disclosure documents. Following a thorough analysi
s, prepared comprehensive, non-confidential marketing material for potential pa
rtners in the pharmaceutical industry. Using business and marketing databases, s
uch as Zoominfo, Mergent Online, and Marketline, identified as potential partner
s several business development executives in specific and non-specific therapeut
ic areas.
Columbia University Medical Center, Associate Scientist: 2008 to 2009.
Designed and executed experiments, implementing known and new protocols if neces
sary, for an on-going drug discovery program. Identified molecules having desir
ed biological effects. Proposed and developed strategies for the production of
new chemical entities (NCEs) that hold promise as new therapies for pain managem
ent. Tested the efficacy of newly created potent molecule analogues. Analyzed
and documented results, confirming the reproducibility and reliability of the ex
periments.
Lundbeck Research USA, Scientist II: 2003 to 2007.
Conducted on-going lab research and analysis on multiple projects in the areas o
f anxiety and depression disorders. Discovered a new class of drug, previously
passing Phase I clinical trials, by optimizing a targeted molecule with improved
physical properties and activity. Published one scientific paper and two paten
ts. Utilized secondary research to explore the merits of a newly defined classi
fied project and to maintain on-going trends in the therapeutic field. Performe
d medicinal chemistry research on specific receptors not covered by the intellec
tual property rights of competing companies. Managed project database of chemic
al and biological information to analyze and interpret results and to guide the
project direction in collaboration with other departments.

Lundbeck Research USA (formerly Synaptic Pharmaceuticals), Scientist I: 2002 to

2003.
Optimized Phase I drug candidate for clinical trials on healthy human volunteers
. Developed and executed strategic research plans for tracking research progres
s and to guarantee Intellectual Property protection on the nominated Phase I tre
atment for anxiety and depression.

Sanofi-Aventis (formerly Sanofi-Synthelabo), Organic Chemist: 2001 - 2001

Contributed to the successful completion of two anti-malaria projects through ch
emical research. Improved the physical and chemical properties of an anti-malari
a compound.

Adolor Corporation, Organic Chemist, 2001 - 2001

Supported research for a marketed drug, Entereg (Alvimopan), a postoperative dru
g to help the bowel recover more quickly following surgery. Generated numerous
analogues (structural derivatives) for Entereg for patent protection.
Education, patents, and publications
1996 * University of Nottingham, PhD, Organic Chemistry
1993 * University of North London, Bachelor of Science (with honors), Chemistry
Patents: Aminoalkoxyphenyl indolone derivatives * PCT #20060173180;
PCT #20060172989
Publications:
1) Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent G
alanin GalR3 receptor binding affinity and improved solubility. Bioorganic Medic
inal Chemistry Letters, 2006, 16(15), 3950

Contact information
Telephone: cell (201) 403-5920 home (973) 423-2987
E-mail: ut103c1fa@westpost.net
Linkedin Profile: http://www.linkedin.com/in/upendratopiwala